221 related articles for article (PubMed ID: 2850890)
1. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
Farrar WL; Harel-Bellan A; Ferris DK
Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD4+ T cell function by the HIV envelope protein, gp120.
Diamond DC; Sleckman BP; Gregory T; Lasky LA; Greenstein JL; Burakoff SJ
J Immunol; 1988 Dec; 141(11):3715-7. PubMed ID: 2846691
[TBL] [Abstract][Full Text] [Related]
3. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
[TBL] [Abstract][Full Text] [Related]
4. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.
Landau NR; Warton M; Littman DR
Nature; 1988 Jul; 334(6178):159-62. PubMed ID: 3260352
[TBL] [Abstract][Full Text] [Related]
5. Recognition of HIV glycoprotein gp120 by T cells. Role of monocyte CD4 in the presentation of gp120.
Siliciano RF; Knall C; Lawton T; Berman P; Gregory T; Reinherz EL
J Immunol; 1989 Mar; 142(5):1506-11. PubMed ID: 2537355
[TBL] [Abstract][Full Text] [Related]
6. HIV infection is blocked in vitro by recombinant soluble CD4.
Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT
Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022
[TBL] [Abstract][Full Text] [Related]
7. Lymphocyte activation by HIV-1 envelope glycoprotein.
Kornfeld H; Cruikshank WW; Pyle SW; Berman JS; Center DM
Nature; 1988 Sep; 335(6189):445-8. PubMed ID: 2843775
[TBL] [Abstract][Full Text] [Related]
8. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
Hussey RE; Richardson NE; Kowalski M; Brown NR; Chang HC; Siliciano RF; Dorfman T; Walker B; Sodroski J; Reinherz EL
Nature; 1988 Jan; 331(6151):78-81. PubMed ID: 2829023
[TBL] [Abstract][Full Text] [Related]
9. Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding.
Clayton LK; Sieh M; Pious DA; Reinherz EL
Nature; 1989 Jun; 339(6225):548-51. PubMed ID: 2543930
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
Traunecker A; Lüke W; Karjalainen K
Nature; 1988 Jan; 331(6151):84-6. PubMed ID: 2829024
[TBL] [Abstract][Full Text] [Related]
11. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
[TBL] [Abstract][Full Text] [Related]
12. Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.
Corbeau P; Benkirane M; Weil R; David C; Emiliani S; Olive D; Mawas C; Serre A; Devaux C
J Immunol; 1993 Jan; 150(1):290-301. PubMed ID: 7678031
[TBL] [Abstract][Full Text] [Related]
13. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
14. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI
Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140
[TBL] [Abstract][Full Text] [Related]
15. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
[TBL] [Abstract][Full Text] [Related]
16. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D
Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809
[TBL] [Abstract][Full Text] [Related]
17. HIV env glycoprotein shares a cross-reacting epitope with a surface protein present on activated human monocytes and involved in antigen presentation.
Beretta A; Grassi F; Pelagi M; Clivio A; Parravicini C; Giovinazzo G; Andronico F; Lopalco L; Verani P; Buttò S
Eur J Immunol; 1987 Dec; 17(12):1793-8. PubMed ID: 2446880
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.
Weinhold KJ; Lyerly HK; Stanley SD; Austin AA; Matthews TJ; Bolognesi DP
J Immunol; 1989 May; 142(9):3091-7. PubMed ID: 2468713
[TBL] [Abstract][Full Text] [Related]
19. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding.
Clayton LK; Hussey RE; Steinbrich R; Ramachandran H; Husain Y; Reinherz EL
Nature; 1988 Sep; 335(6188):363-6. PubMed ID: 2843773
[TBL] [Abstract][Full Text] [Related]
20. HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis.
Mann DL; Lasane F; Popovic M; Arthur LO; Robey WG; Blattner WA; Newman MJ
J Immunol; 1987 Apr; 138(8):2640-4. PubMed ID: 3031162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
